phrykt

Harvard Apparatus Regenerative Technology, Inc. (HRGN): who owns it and who trades it

As of Oct 30, 2026, HRGN insiders reported 3 purchases worth $400K in the last 12 months. The largest buyer was Junli He (CEO), with $400K.

Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, HRGN insiders reported $400K of open-market purchases and $0 of sales.

Purchases, 12 months
$400K
3 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Sep 15, 2026
Filed Sep 25, 2026

Purchases and sales by month

$394K$394KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 15, 2026Junli HeCEOPurchase6,725$2.15$14.5KForm 4
Sep 11, 2026Junli HeCEOPurchase361,905$1.05$380KForm 4
Nov 25, 2025Junli HeCEOPurchase3,000$1.70$5.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Junli HeCEO, Director$400K–Sep 15, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

HRGN short interest

Low short interest. Less than 0.1% of HRGN shares are sold short. Over the last 12 reports the number of shares short went up 1588%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1,013 HRGN shares were sold short, 0.0% of the shares outstanding, up 48.3% from the report before. At the average daily volume of 2,630 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.01%May 15Oct 300.03%

Days to cover

1.0May 15Oct 304.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261,0130.01%+48%2,6301.0
Oct 15, 20266830.00%+9%2,3921.0
Sep 30, 20266250.00%-84%3,2441.0
Sep 15, 20263,9160.02%+572%7,0691.0
Aug 31, 20265830.00%No change4441.3
Aug 14, 20265830.00%-3%3,7371.0
Jul 31, 20266030.00%No change1414.3
Jul 15, 20266030.00%-29%7,8381.0
Jun 30, 20268450.00%+54%1,1871.0
Jun 15, 20265490.00%+3129%1,4681.0
May 29, 2026170.00%-72%1,3901.0
May 15, 2026600.00%-63%1,5061.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Harvard Apparatus Regenerative Technology company events

Harvard Apparatus Regenerative Technology filed 7 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Sep 14, 2026.

  1. Sep 14, 2026AgreementHarvard Apparatus Regenerative Technology, Inc. entered into Securities Purchase Agreements with certain investors pursuant to which the Investors agreed to purchase in a private placement an aggregate of 2,703,727 shares of common stock for an aggregate purchase price of $2.84 million and a… Filing
  2. Aug 3, 2026AgreementHarvard Apparatus Regenerative Technology, Inc. entered into a loan arrangement with Junli He, the Chairman and Chief Executive Officer of the Company, pursuant to which the Lender agreed to loan the Company an aggregate amount of $200,000 as evidenced by a Bridge Note executed by the Company in… Filing
  3. Aug 3, 2026AgreementAmended an earlier report. This Amendment is being filed to report the matters previously disclosed in the Original Report under the correct Item. Filing
  4. Jun 24, 2026VoteReported shareholder vote results. Filing
  5. Apr 28, 2026AnnouncementShared information with investors. Filing
  6. Apr 15, 2026AgreementEnded an important agreement. Filing
  7. Jan 6, 2026AgreementHarvard Apparatus Regenerative Technology, Inc. entered into Securities Purchase Agreements, each effective as of December 30, 2025, with certain investors pursuant to which the Investors agreed to purchase in a private placement an aggregate of 411,765 shares of common stock for the aggregate… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Harvard Apparatus Regenerative Technology financials

Questions about Harvard Apparatus Regenerative Technology, Inc. (HRGN) stock

Are HRGN insiders buying or selling?

In the last 12 months, HRGN insiders reported 3 open-market purchases worth $400K and no sales. The latest trade was on Sep 15, 2026. See every trade.

What is the short interest in HRGN?

As of Oct 30, 2026, 1,013 HRGN shares were sold short, 0.0% of the shares outstanding, up 48.3% from the report before. At the average daily volume of 2,630 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Executive pay

Harvard Apparatus Regenerative Technology's chief executive was paid a total of $440K for the year ended Dec 31, 2025, down 66% from $1.3M the year before. In the last 12 months, Harvard Apparatus Regenerative Technology's executives and directors bought $400K of stock on the open market and sold none.

Chief executive, total pay$440KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$365KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$209KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.